In–licensing agreement for the combination painkiller Maxigesic of AFTĪcquisition of MENA operations and product rights of Norgine B.V.Īquisition of Takeda’s manufacturing plant in Põlva, Estoniaĭivestment of Acino’s transdermal and implant business to Luye Pharma Ltd. Move of the Headquarters to Zurich and start of a substantial re-organization in Switzerland Litha announces divestment of medical and vaccine businessĮndo completes acquisition of Aspen product portfolio Litha Healthcare Group changes to (Pty) Ltd.
effectively owning 65% of Litha Healthcare Group LimitedĮndo and LHG announce intent to acquire balance of Litha sharesĮndo International plc, completes 100% acquisition of Litha Healthcare Group Limited. Takeover by Avista Capital and Nordic CapitalĮndo International plc, offers to acquired Paladin Labs Inc.Īcino is delisted from the stock exchangeĮndo International plc, completes acquisition pf Paladin Labs Inc. LHG purchases 100% of Pharmaplan for R590 m and merges business with Litha Pharma Division LHG acquires Goldex Healthcare and OTC Pharma SA International NDB signed with Cpoint Capital Inc. Commercialization of products under the brand “Acino Switzerland” Name Changes to Litha Health Care Holdings (LHH)Ĭhange of the group and subsidiaries name to AcinoĬompleted funding and planning for Biovac vaccine manufacturing site CTĪcquisition of combined Middle East and African Business of Cephalon Acquisition of Mepha’s production and R&D facilities and the business in MEA, LATAM and Asia.
Litha Investments purchase extra 11% of Biovac Holdings
Our focus on emerging markets has since seen the acquisition of leading phramaceutical manufacturing and commercial organisations, including in South Africa.īiovac Holdings sold 40% stake to Litha Investment Groupīiovac Consortium awarded contract with SA goverment in forming a PPP The Biovac Institute In 1994, the company went public on the Swiss stock exchange (SIX: ACIN) and gradually streamlined its business to focus on chemicals, pharmaceuticals and biotechnology. The subsequent years saw a focusing of the company’s activities on advanced drug delivery with the acquisition of Cimex Pharma AG, a Swiss supplier of complex solid oral dosage forms, in 2004, and of Novosis AG, Europe’s second largest manufacturer of transdermal patches and of biodegradable implants, in 2006. Subsequently, the company widened its activities to become both a manufacturer and trader and enlarged its portfolio with value added products including chemical specialties such as feeding stuffs, fertilizers and active pharmaceutical ingredients. The origins of the Acino – which was named “Schweizerhall” until 2008 – date back to 1836 when the company was founded around a saltworks operation near Basel, Switzerland. Our History A long-established and proven track record
0 kommentar(er)
